NAAG Urges Facebook to Abandon Plans to Develop Instagram Kids

It appears that Facebook is not responding to a need, but instead creating one, as this platform appeals primarily to children who otherwise do not or would not have an Instagram account. In short, an Instagram platform for young children is harmful for myriad reasons. The attorneys general urge Facebook to abandon its plans to launch this new platform.

Read More →

NAAG Submits Comment Letter on Beneficial Ownership Regulations

Our comments are consistent with the sense of Congress, which requires that regulations “to the greatest extent practicable… collect information in a form and manner that is reasonably designed to generate a database that is highly useful to… law enforcement agencies…” NDAA § 6402(8)(C).

Read More →

NAAG Supports Funding for Legal Services Corporation (LSC)

LSC funding has also fostered public-private partnerships between legal aid
organizations and private firms and attorneys across the country which donate their
time and skills to assist residents in need. Nationwide, 132 independent nonprofit
legal aid programs rely on this federal funding to provide services to nearly two
million of our constituents on an annual basis.

Read More →

NAAG Endorses EAGLES Act

No one person or entity can achieve these goals alone. Preventing targeted violence demands a multi-faceted approach toward a solution and calls for coordination among law enforcement officials, lawmakers, educators, parents and students, and community members. Moreover, reducing targeted violence in our schools requires partnership between state and federal agencies – precisely the type of collaboration contemplated by the EAGLES Act.

Read More →

NAAG Urges OfferUp to Prevent the Sales of Fraudulent Vaccine Cards

The false and deceptive marketing and sales of fake COVID vaccine cards threatens the health of our communities, slows progress in getting our residents protected from the virus, and are a violation of the laws of many states.

Read More →

NAAG Works to Prevent the Online Sale of Fraudulent COVID Vaccination Cards

The false and deceptive marketing and sales of fake COVID vaccine cards threaten the health of our communities, slow progress in getting our residents protected from the virus, and are a violation of the laws of many states.

Read More →

State of Wisconsin et al. v. Indivior, No. 16-5073 (E.D. Pa. Sept. 22,2016)

Plaintiff states alleged that the makers of Suboxone, a drug used to treat opioid addiction, engaged in a scheme to block generic competitors and raise prices. Specifically, they are conspiring to wtich Suboxone from a tablet version to a flim in order to prevent or delay generic entry. The states allege that the manufacturers engaged in “product hopping” in which a company makes slight changes to its product to extend patent protections and prvent generic alternatives. The complaint was filed under seal.

Read More →

Texas et al. v. Organon (Remeron), No. 04-5126 (D.N.J. 2004)

Plaintiff states settled with drug maker Organon USA, Inc. and its parent company, Akzo Nobel N.V., resolving antitrust claims involving the antidepressant drug Remeron between June 2001 and October 2004. The states’ complaint alleged that Organon unlawfully extended its monopoly by improperly listing a new “combination therapy” patent with the U.S. Federal Drug Administration. In addition, the complaint alleged that Organon delayed listing the patent with the FDA in another effort to delay the availability of lower-cost generic substitutes. The $26 million settlement resolved claims brought by state attorneys general, as well as a private class action brought on behalf of a class of end payors. Organon also agreed to make timely listings of patents and to submit accurate and truthful information to the FDA.

Read More →

In the Matter of GlaxoSmithKline, PLC (Augmentin)

States alleged that GlaxoSmithKline fraudulently obtained patent protection for Augmentin and then delayed generic entry through sham patent litigation. Through this conduct, GlaxoSmithKline unlawfully maintained its monopoly over Augmentin. A $3.5 million multistate settlement for state proprietary claims was entered into by the participating states and GlaxoSmithKline.

Read More →

Ohio, et al, v. Bristol-Myers Squibb Co., et al.(D.D.C. 2002); see also In re Buspirone Antitrust Litigation,Case No. 01 CV 11401, MDL 1410, MDL 1413 (S .D.N.Y.)

Plaintiff States sought damages and injunctive relief, alleging that the drug company, Bristol-Myers Squibb, Co. (BMS) wrongfully maintained a monopoly on Taxol, a drug for which the Plaintiff States alleged Defendant fraudulently filed a patent. BMS’s alleged wrongful action delayed entry into the market by generic competitors of the drug, resulting in higher prices for Taxol. In 2008, plaintiff states sued BMS for failing to report accurately to the states, pursuant to the settlemen, a patent arrangement involving the drug Plavix. The company pleaded guilty to lying to the FTC and the states recovered $1.1 million in fines.

Read More →